First-line Nivolumab (anti-PD-1) Monotherapy in Advanced NSCLC: the Story of Immune Checkpoint Inhibitors and "the Sorcerers Apprentice"

Overview

Journal Transl Lung Cancer Res

Date 2015 Jul 25

PMID 26207206

Citations 8

Authors

Gerald Schmid-Bindert

Tao Jiang

Affiliations

Soon will be listed here.

Citing Articles

Machine learning-based identification of glycosyltransferase-related mRNAs for improving outcomes and the anti-tumor therapeutic response of gliomas.

Zhang C, Zhou W Front Pharmacol. 2023; 14:1200795.

PMID: 37663248 PMC: 10468601. DOI: 10.3389/fphar.2023.1200795.

Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis.

Akarca F, Can O, Yalcinli S, Altunci Y Turk J Emerg Med. 2018; 17(4):157-159.

PMID: 29464222 PMC: 5812893. DOI: 10.1016/j.tjem.2017.05.007.

Bilateral uveitis and macular edema induced by Nivolumab: a case report.

Theillac C, Straub M, Breton A, Thomas L, Dalle S BMC Ophthalmol. 2017; 17(1):227.

PMID: 29195497 PMC: 5709862. DOI: 10.1186/s12886-017-0611-3.

Dynamics of Heat Shock Protein 70 Serum Levels As a Predictor of Clinical Response in Non-Small-Cell Lung Cancer and Correlation with the Hypoxia-Related Marker Osteopontin.

Ostheimer C, Gunther S, Bache M, Vordermark D, Multhoff G Front Immunol. 2017; 8:1305.

PMID: 29093708 PMC: 5651249. DOI: 10.3389/fimmu.2017.01305.

Effective antitumor peptide vaccines can induce severe autoimmune pathology.

Sultan H, Trillo-Tinoco J, Rodriguez P, Celis E Oncotarget. 2017; 8(41):70317-70331.

PMID: 29050282 PMC: 5642557. DOI: 10.18632/oncotarget.19688.

References

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View